Alzheimer's Research & Therapy
Striatal amyloid is associated with tauopathy and memory decline in familial Alzheimer’s disease
- Bernard J. Hanseeuw,
- Francisco Lopera,
- Reisa A. Sperling,
- Daniel J. Norton,
- Edmarie Guzman-Velez,
- Ana Baena,
- Enmanuelle Pardilla-Delgado,
- Aaron P. Schultz,
- Jennifer Gatchel,
- David Jin,
- Kewei Chen,
- Eric M. Reiman,
- Keith A. Johnson† and
- Yakeel T. Quiroz†
†Contributed equally
Alzheimer's Research & Therapy201911:17
© The Author(s). 2019
- Received: 6 November 2018
- Accepted: 14 January 2019
- Published: 4 February 2019
Abstract
Background
Autosomal dominant Alzheimer’s disease (ADAD) is distinguished from late-onset AD by early striatal amyloid-β deposition. To determine whether striatal Pittsburgh compound B (PiB)-PET measurements of amyloid-β can help predict disease severity in ADAD, we compared relationships of striatal and neocortical PiB-PET to age, tau-PET, and memory performance in the Colombian Presenilin 1 E280A kindred.
Methods
Fourteen carriers (age = 28–42, Mini-Mental State Examination = 26–30) and 20 age-matched non-carriers were evaluated using PiB, flortaucipir (FTP; tau), and memory testing (CERAD Word List Learning). PiB-PET signal was measured in neocortical and striatal aggregates. FTP-PET signal was measured in entorhinal cortex.
Results
Compared to non-carriers, mutation carriers had age-related elevations in both neocortical and striatal PiB binding. The PiB elevation in carriers was significantly greater in the striatum than in the neocortex. In mutation carriers, PiB binding in both the neocortex and the striatum is related to entorhinal FTP; however, the association was stronger with the striatum. Only striatal PiB was associated with worse memory. Remarkably, PiB binding in the striatum, but not in the neocortex, predicted entorhinal FTP and lower memory scores after adjusting for age, indicating that striatal PiB identified the carriers with the most severe disease.
Conclusions
Based on these preliminary cross-sectional findings, striatal PiB-PET measurements may offer particular value in the detection and tracking of preclinical ADAD, informing a mutation carrier’s prognosis and evaluating amyloid-β-modifying ADAD treatments.
Keywords
- Early-onset autosomal dominant Alzheimer’s disease
- Striatum
- Tau PET
- Amyloid PET
- Memory
No hay comentarios:
Publicar un comentario